Amarin To Report Third Quarter 2018 Results and Host Conference Call On November 1, 2018
October 25 2018 - 6:00AM
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health, today announced that it will
host a conference call with members of Amarin senior management to
discuss the company's third quarter 2018 financial results and
provide an operational update on November 1 at 7:30 a.m. EDT. The
conference call will follow the anticipated release of the
company's financial results earlier that day. No additional
information regarding the results of the cardiovascular outcomes
study of Vascepa, the REDUCE-IT study, will be provided during this
call. As previously announced, Amarin looks forward to such
outcomes study results being presented at the 2018 Scientific
Sessions of the American Heart Association (AHA) on November 10,
2018 in Chicago, Illinois.
Event Details:
The conference call can be heard live on the
investor relations section of the company's website at
www.amarincorp.com, or via telephone by dialing 877-407-8033 within
the United States or 201-689-8033 from outside the United States. A
replay of the call will be made available for a period of two weeks
following the conference call. To hear a replay of the call, dial
877-481-4010. A replay of the call will also be available through
the company's website shortly after the call. For both dial-in
numbers please use PIN: 38108.
To Ask Questions:
During the teleconference, following prepared
remarks, management will respond to questions from investors and
analysts, subject to time limitations. Participants in the live
teleconference will be provided an opportunity to ask questions.
Investors may also e-mail their questions to
investor.relations@amarincorp.com. E-mail questions will be
accepted until 4:00 p.m. ET on Wednesday, October 31, 2018.
About Amarin
Amarin Corporation plc. is a rapidly growing,
innovative pharmaceutical company focused on developing
therapeutics to improve cardiovascular health. Amarin’s product
development program leverages its extensive experience in lipid
science and the potential therapeutic benefits of polyunsaturated
fatty acids. Vascepa (icosapent ethyl) is Amarin's first
FDA-approved drug and is available by prescription in the United
States, Lebanon and the United Arab Emirates. Amarin’s
commercial partners are pursuing additional regulatory approvals
for Vascepa in Canada, China and the Middle East. For more
information about Amarin, visit www.amarincorp.com.
Availability of Other Information About
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (http://www.amarincorp.com/), the investor relations
website (http://investor.amarincorp.com/), including but not
limited to investor presentations and investor FAQs, Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Amarin posts on
these channels and websites could be deemed to be material
information. As a result, Amarin encourages investors, the
media, and others interested in Amarin to review the information
that is posted on these channels, including the investor relations
website, on a regular basis. This list of channels may be
updated from time to time on Amarin’s investor relations website
and may include social media channels. The contents of
Amarin’s website or these channels, or any other website that may
be accessed from its website or these channels, shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933.
Amarin Contact Information
Investor Relations:Elisabeth Schwartz Investor
Relations and Corporate Communications Amarin Corporation plc
In U.S.: +1 (908) 719-1315 investor.relations@amarincorp.com
Lee M. Stern Trout Group In U.S.: +1 (646)
378-2992lstern@troutgroup.com Media Inquiries: Christy Maginn
Burson-Marsteller In U.S.: +1 (646) 280-5210
Christy.Maginn@bm.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024